AMRI Adds Custom API Capabilities

Published on: 

AMRI’s acquisition of Euticals expands its API development and manufacturing business.

AMRI announced on May 5, 2016, that agreed to acquire all outstanding shares of Prime European Therapeuticals (Euticals) in a transaction valued at approximately $358 million (EUR 315 million), consisting of shares of AMRI common stock, cash, and a seller note. Euticals, privately-held company headquartered in Lodi, Italy, specializes in custom API synthesis and manufacturing, with facilities in Italy, Germany, the United States, and France and has a base of more than 400 customers. 

The acquisition provides AMRI with a custom synthesis presence in Europe and expands expertise in sterile API, steroids, generics, fermentation, controlled substances, and monobactams.

Provides an API portfolio that includes 50 active US Drug Master Files (DMFs), 17 EU Certificates of Suitability (COS) or Compliance with the European Pharmacopeia (CEP), 13 Japanese DMFs and 6 South Korean DMFs; wth several APIs having filings in more than one of these areas and over two dozen other international filings


Fernando Napolitano will join the Board of Directors on behalf of Lauro Cinquantesette, S.p.A (Lauro 57) and its majority investors, Clessidra Capital Partners II and Mandarin Capital Partner SCA SICAR. Margalit Fine, Euticals' chief executive officer and former head of European API at Teva, will be leading Euticals' operations as a senior executive for the combined company, the company reports.

Source: AMRI